Ependymoma Clinical Trials 2023

What are the top hospitals conducting ependymoma research?

In the realm of cutting-edge clinical trials for ependymoma, several hospitals across the United States are leading the charge. One such institution is Memorial Sloan Kettering Cancer Center in New york City, which boasts an impressive 21 ongoing trials dedicated to this rare type of brain cancer. With a total of 24 completed ependymoma trials since their first recorded study in 2009, Memorial Sloan Kettering has been at the forefront of groundbreaking research in this field. In Los Angeles, Children's Hospital Los Angeles stands out with 19 active ependymoma trials and a noteworthy record of 23 previous studies dating back to their initial trial in 1997.

Meanwhile, Cincinnati Children's Hospital Medical Center has established itself as a prominent hub for researching ependymoma with an impressive lineup of 18 ongoing clinical trials and a remarkable history encompassing 27 prior investigations since initiating studies on this specific tumor type back in 2003. At Children's Hospital Colorado located in Aurora, medical experts are currently spearheading efforts with17 active ependymoma clinical trials while having conducted a commendable number of twenty previous studies since their inaugural trial focusing on this condition commenced just over a decade ago in2010.Arnold Palmer Hospital for Children situated within Orlando also plays its part by facilitating seventeen ongoing ependymoma clinical tests along with contributing towards nineteen previously executed investigations for tackling this disease; theirs have been witnessed starting from early experiments performed back duringthe year2004

These renowned hospitals exemplify not only remarkable dedication but also serve as beacons of hope when it comes to advancing our understanding and treatment options for patients diagnosed with ependymoma. The collective endeavors carried out by these institutions demonstrate that progress is being made every day toward finding effective solutions and improving outcomes for individuals affected by this challenging brain tumor

Which are the best cities for ependymoma clinical trials?

When it comes to ependymoma clinical trials, several cities stand out as hubs of research and development. New york leads the pack with 55 active trials, investigating treatments like Pharmacological Study, Tazemetostat, and Tipifarnib. Orlando is not far behind with 48 ongoing studies focused on approaches such as Pharmacological Study, 3-Dimensional Conformal Radiation Therapy, and Vemurafenib. Additionally, Saint Louis boasts 44 active trials exploring options like Pharmacological Study and Vemurafenib coupled with 3-Dimensional Conformal Radiation Therapy. These cities offer individuals diagnosed with ependymoma access to cutting-edge clinical trials that provide hope for improved treatment outcomes.

Which are the top treatments for ependymoma being explored in clinical trials?

The field of ependymoma research is rapidly advancing, with several exciting treatments being explored in clinical trials. Some of the top contenders include:

• Pharmacological Study: Currently involved in 3 active trials and boasting a total of 9 all-time ependymoma trials since its introduction in 2010.
• ONC206: This promising treatment is currently being tested in 2 active trials and has shown potential, despite having only 2 all-time ependymoma trials to its name so far (first listed in 2020).
• Ibrutinib: Although relatively new on the scene (first listed in 2022), it shows promise as an effective treatment for ependymoma and is currently undergoing one active trial.
• SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel: This innovative therapy has also garnered significant attention, participating in one active trial among the single all-time ependymoma trial recorded since its listing in 2019.
• Partial Radiation: Another approach being investigated involves partial radiation, which currently has one ongoing trial dedicated to studying its efficacy against this challenging cancer type.

As researchers continue their endeavors, these treatments offer hope for patients battling ependymoma.

What are the most recent clinical trials for ependymoma?

Recent clinical trials for ependymoma offer hope and potential advancements in treatment options. One trial, known as Arm A, focuses on relapsed or refractory central nervous system tumors, including ependymoma. Another study explores the use of LUTATHERA® (Lutetium Lu 177 dotatate) and its efficacy in treating this type of cancer. Additionally, a Phase 1 trial investigates the effectiveness of HER2 Specific CAR T Cell therapy specifically designed for patients with ependymoma. Furthermore, SurVaxM is being studied as a treatment option for patients aged 10 to 21 with relapsed or progressive medulloblastoma, high-grade gliomas (HGG), or ependymoma. Lastly, activated T cells are being evaluated in a Phase 1 trial targeting ependymoma cases. These ongoing research efforts provide optimism and possible breakthroughs in managing this challenging condition.

What ependymoma clinical trials were recently completed?

Recently completed clinical trials have brought significant progress in the field of ependymoma research. These trials include a study on GDC-0084, led by The Royal Marsden NHS Foundation Trust and Cancer Research UK, which concluded in October 2021. Additionally, St. Jude Children's Research Hospital conducted a trial investigating the efficacy of ACNS1422 in August 2021. These endeavors highlight the commitment of researchers to advance treatment options for patients with ependymoma, bringing hope for improved outcomes and quality of life.